Abstract:Emerging evidence suggests that epithelial-mesenchymal transitions (EMTs) play important roles in tumor metastasis and recurrence. Understanding molecular mechanisms that regulate the EMT process is crucial for improving treatment of hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) play important roles in HCC; however, the mechanisms by which miRNAs target the EMT and their therapeutic potential remains largely unknown. To better explore the roles of miRNAs in the EMT process, we established an EMT model in HCC cells by transforming growth factor beta 1 treatment and found that several tumor-related miRNAs were significantly decreased. Among these miRNAs, miR-125b expression was most strongly suppressed. We also found down-regulation of miR-125b in most HCC cells and clinical specimens, which correlated with cellular differentiation in HCC patients. We then demonstrated that miR-125b overexpression attenuated EMT phenotype in HCC cancer cells, whereas knockdown of miR-125b promoted the EMT phenotype in vitro and in vivo. Moreover, we found that miR-125b attenuated EMT-associated traits, including chemoresistance, migration, and stemness in HCC cells, and negatively correlated with EMT and cancer stem cell (CSC) marker expressions in HCC specimens. miR-125b overexpression could inhibit CSC generation and decrease tumor incidence in the mouse xenograft model. Mechanistically, our data revealed that miR-125b suppressed EMT and EMT-associated traits of HCC cells by targeting small mothers against decapentaplegic (SMAD)2 and 4. Most important, the therapeutic delivery of synthetic miR-125b mimics decreased the target molecule of CSC and inhibited metastasis in the mice model. These findings suggest a potential therapeutic treatment of miR-125b for liver cancer. Conclusion: miR-125b exerts inhibitory effects on EMT and EMT-associated traits in HCC by SMAD2 and 4. Ectopic expression of miR-125b provides a promising strategy to treat HCC. (Hepatology 2015;62:801-815)

Mir-125B-5p Enhances Chemotherapy Sensitivity to Cisplatin by Down-Regulating Bcl2 in Gallbladder Cancer

Mir-145 Sensitizes Gallbladder Cancer to Cisplatin by Regulating Multidrug Resistance Associated Protein 1

MiR-125b Promotes Cell Migration and Invasion by Targeting PPP1CA-Rb Signal Pathways in Gastric Cancer, Resulting in a Poor Prognosis

Mir-223 Increases Gallbladder Cancer Cell Sensitivity to Docetaxel by Downregulating STMN1.

MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.

Effect of Mir-125B by Targeting Inhibition of BCL2 and MCL1 on Multidrug Resistance of Human Gastric Cancer Cell Line

Mir-125B Promotes Colorectal Cancer Migration and Invasion by Dual-Targeting CFTR and CGN

Downregulation of Mir-33A-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.

Mir-218-5p Restores Sensitivity to Gemcitabine Through PRKCE/MDR1 Axis in Gallbladder Cancer

miR-125b increases sensitivity of CD133+ colorectal cancer cells to cisplatin by down-regulating HAX-1 expression

Circulating MiR-125b As a Marker Predicting Chemoresistance in Breast Cancer

Mir-122 Inhibits Cancer Cell Malignancy by Targeting PKM2 in Gallbladder Carcinoma

IDDF2019-ABS-0246 LncRNA XIST Regulated Chemotherapeutic Sensitivity of Mir-125B-2–3p by Targeting Wee1 in Colorectal Cancer

MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4.

Upregulated Mir-182 Increases Drug Resistance in Cisplatin-Treated HCC Cell by Regulating TP53INP1.

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

MiR-125a Promotes Paclitaxel Sensitivity in Cervical Cancer Through Altering STAT3 Expression

Cisplatin-induced Epigenetic Activation of Mir-34A Sensitizes Bladder Cancer Cells to Chemotherapy

MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1

Overexpression of Microrna-125B Sensitizes Human Hepatocellular Carcinoma Cells to 5-Fluorouracil Through Inhibition of Glycolysis by Targeting Hexokinase II

[Mir-503 Sensitizes Human Hepatocellular Carcinoma Cells to Cisplatin by Targeting Bcl-2].